Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS MOVES FFR ACTIVITIES TO INCREASE MANUFACTURING CAPACITY

17 June 2015

Quebec City, Quebec, June 25, 2015 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) announces that in light of the positive feedback on the performance of its products developed to measure Fractional Flow Reserve (“FFR”), the OptoWire and OptoMonitor (“Opsens’ FFR products”), and the recent FDA approval for the commercialization of these products in…

Read more

OPSENS GETS CLEARANCE TO SELL FFR PRODUCTS IN THE UNITED STATES

15 June 2015

Quebec City, Quebec, June 15, 2015 – Opsens Inc. (TSXV:OPS) (OTCQX:OPSSF) (“Opsens” or the “Company”) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the OptoWire and OptoMonitor, its products developed to measure Fractional Flow Reserve (“FFR”). This measure is used to optimize the diagnostic and guide the treatment of patients…

Read more